China gets rid of malaria

Infants and younger children to stay under immediate care of parents/guardians

After Mucormycosis, can Multisystem Inflammatory Syndrome (MIS-C) play havoc in India in the wake of the COVID-19 pandemic?

When the worst does its best, even the rarest makes it to the commonest. An otherwise rare infection — mucormycosis — has emerged as a serious health crisis amid the ravaging second wave of COVID-19 in India.

The possibility of infections caused by the fungus Aspergillus in people with severe COVID-19 is still debated by scientists. In the past, Aspergillosis was reported only from people with severely weakened immune systems.

High doses of immunity suppressing medicines for prolonged duration in COVID-19 can increase risk of mucormycosis in COVID. Drugs like steroids, at high doses, immunosuppressants like Tociluzumab, baricitinib, bevacizumab and tofacitinib can predispose an individual to mucormycosis.

One baby is born with familial hypercholesterolemia every minute. FH is underdiagnosed and undertreated globally. Familial hypercholesterolemia (FH) is an inherited condition leading to severely elevated serum low density lipoprotein cholesterol (LDL-C) that leads to premature atherosclerotic cardiovascular disease (ASCVD) and accounts for 2–3% of the cases of myocardial infarction in patients aged less than […]